News | March 12, 2024
AbCellera and Biogen collaborate on neurological antibody therapy
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Sustainability is integral to Biocon's business purpose
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
